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Abstract
Background: Despite high levels of equipment distribution through Needle and Syringe Programmes (NSPs) in
Australia, the levels of reuse of equipment among people who inject drugs remain concerning. This paper used an
exploratory analysis to examine the needs of NSP client that could be addressed by NSPs to enhance service
impact and blood-borne virus risk practices.
Methods: People who inject drugs were recruited from six NSP sites in Sydney, Australia, to undertake a
self-completed survey.
Results: Using the responses of 236 NSP client participants, three factors were identified in an exploratory factor
analysis: recent risky injection (Eigenvalue 3.63, 20.2 % of variance); disadvantage and disability (Eigenvalue 2.26, 12.
5 % of variance); and drug use milieu (Eigenvalue 1.50, 8.4 % of variance). To understand the distribution of these
factors, the standardised factor scores were dichotomised to explore those participants with ‘above average’
vulnerability on each factor. A small group of NSP clients reported a cluster of vulnerability measures. Most
participants (55.5 %) reported vulnerability on none or only one factor, indicating that 45.5 % could be considered
as having double (35.6 %) or triple (8.9 %) vulnerability.
Conclusions: These results challenge NSPs to understand the heterogeneity among their client group and develop
programmes that respond to their clients’ range of needs beyond those immediately associated with blood-borne
virus (BBV) risk. This paper contributes to the growing evidence base regarding the need for BBV prevention efforts
to examine strategies beyond equipment distribution.
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Background
A key response to the transmission of blood-borne viruses
(BBVs) among people who inject drugs (PWID) is the
provision of sterile injecting equipment [1, 2]. Providing
injecting equipment, while necessary, does not adequately
address all of the needs of PWID. However, there is little
guidance in the literature on the extent and variety of
Needle and Syringe Programme (NSP) client needs and the
association of these with BBV risk practices. In the field of
HIV and injecting drug use, where the evidence is stron-
gest, combined prevention interventions are considered as
the provision of sterile injecting equipment, opiate substi-
tution treatment and access to HIV treatments [3]. These
interventions, while undoubtedly important, cannot ad-
dress the broader range of variables shown to impact BBV
risk and cannot account for inter-relationships between
these variables. This leaves NSPs potentially delivering less
than optimal services if their service delivery model con-
centrates solely on access to sterile injecting equipment
without considering broader client needs, particularly in a
context such as Australia with high levels of distribution of
equipment.
Australia has world-leading rates of equipment distri-
bution for PWID [4]. However, reuse of injecting* Correspondence: c.treloar@unsw.edu.au
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equipment remains a critical concern even among PWID
attending NSPs. Approximately one in four Australian
NSP clients reused their own equipment in the previous
month, about 16 % shared others’ needles and syringes
(receptive needle and syringe sharing) and nearly 30 %
shared others’ injecting equipment (receptive equipment
sharing) in the previous month [5]. Such sustained
levels of unsafe injection could be partially reduced by
further increasing syringe coverage as evidence suggests
that approximately one in five Australian NSP clients
[6] and around one-third of Australian NSP pharmacy
scheme attendees [7] do not have adequate sterile
injecting equipment. It is obvious that other factors,
over and above the availability of sterile injecting equip-
ment, must also contribute to the continued practices
of sharing of needles, syringes and other injecting
equipment among PWID [7].
How should NSPs increase their effectiveness in ser-
vice delivery in order to prevent transmission of hepa-
titis C and other BBVs in a context of high levels of
equipment distribution? The risk environment frame-
work has generated a body of research addressing the
physical, social, economic and policy factors that not
only enable PWID to enact safe injecting practices
[8–12] but also enhance the effectiveness of NSP ser-
vice provision [13–17]. A range of factors has been found
to impinge on the capacity of PWID to reduce a broad
spectrum of injection-related injuries and harms. The key
factors in the literature include socioeconomic disadvan-
tage (poverty, unemployment, homelessness and depend-
ence on social welfare dependence), health constraints
due to both physical and mental illnesses [18–26] and
cognitive-behavioural factors [27, 28], as well as injected-
related contextual factors (e.g., injecting in public spaces)
[29–31]) and peer networks [32–34].
The development and current implementation of NSP
policies and service delivery models in Australia, how-
ever, has primarily drawn upon BBV prevention princi-
ples that privilege increased equipment distribution
rather than addressing a range of client-prioritised needs
[35–38]. In this exploratory paper, we aim to better
understand how NSPs could potentially enhance their
service impact by addressing a range of client-focused
needs. To achieve this, rather than adopting the more
conventional approach of soliciting independent predic-
tors of unsafe injection, we used an innovative client
segmentation approach to investigate factors empirically
differentiating NSP clients on the basis of their potential
service needs including but not limited to obtaining ster-
ile injecting equipment.
Methods
Convenience sampling was used across six NSP sites
within a region of Sydney, Australia. The recruitment
sites, which were purposefully selected to represent the
range of publicly funded NSP services in this area, included
two primary NSPs (stand-alone services with specialist
staff) with co-located vending machine sites, two primary
NSP-only sites, and two secondary NSPs (where equipment
distribution is performed by staff in another health services
such as community health or sexual health).
All clients who attended one of six NSP sites over the
study period from October 2012 to February 2013 were
eligible to participate. On the days that researchers were
present, NSP staff informed clients about the study and
then directed interested clients to on-site researchers
who explained to clients what the study was about and
provided them with an information sheet to read. At the
vending machine sites, a flyer was posted on the machine
and the two researchers invited potential candidates to
participate once they had accessed their equipment. In
addition, a small number of participants were referred to
the study by their peers.
Ethics, consent and permissions
Consenting clients completed the survey either on a
touchscreen computer within the NSP or on paper and
returned by mail. Participants were provided with $20 vou-
cher to compensate them for their time. The study had eth-
ics approval from the Human Research Ethics Committee
at the University of New South Wales (HC12128) and rele-
vant health authorities (2011/11/4.6/(3413)).
Survey instruments and measurements
Risky drug injection practices
Risky injecting practices in the past month was measured
by eight recoded, binary variables: (1) reuse of any needles
or syringes (used by oneself or others); (2) receptive injec-
tion (injected by others rather than self-injection); (3) re-
ceptive sharing of any needles or syringes; (4) receptive
sharing of any injecting equipment other than needles or
syringes; (5) distributive sharing of any needles; (6) dis-
tributive sharing of any injecting equipment other than
needles or syringes; (7) injection at least once per day; and
(8) injection at public spaces (e.g., toilets or parks).
Demographic, general health and wellbeing and injection-
specific indicators
Apart from age, gender, country of birth (recoded into
Australian-born vs. other), sexual minority status (recoded
into heterosexual vs. other), Aboriginal or Torres Strait
Islander (ATSI) status (yes or no) and highest level of edu-
cation attainment (recoded into up to year 10 high school
only vs. other), key demographic indicators included: so-
cial welfare dependence (recoded into social welfare being
the main source of current income vs. other); and history
of imprisonment (yes or no).
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Key indicators of general health and wellbeing included:
poor self-rated health (recoded into being ‘fair’ or ‘poor’ vs.
other); daily life stress (recoded into having more than two
major life stressors in the past 12 months vs. other); history
of any diagnoses of mental illness ever (yes or no); and ex-
istence of comorbidities (i.e., chronic physical or mental
complaints) other than hepatitis C infection (yes or no).
Injection-related specific indicators included a history
of injection-caused injuries not related to hepatitis C
(recoded into having more than two health problems vs.
other); perceived current difficulties in managing drug
use (yes or no); having ‘some’, ‘most’ or ‘all’ friends being
PWID (yes or no); and having spent ‘some’, ‘most’ or ‘all’
current free time with other PWID (yes or no).
Data analysis
To identify major clustering variables that potentially
differentiated participants, exploratory, latent factor ana-
lysis was used in the first step. Based on our extensive
knowledge from the literature and previous findings
from this project [39–41], 18 dummy coded variables
(Table 1) were selected for exploratory factor analysis. In
particular, these 18 indicator variables were chosen as
they directly matched with major services that are or
could be provided or facilitated by NSPs, namely, supply
of clean needles, syringes and other injecting equipment,
management of drug addiction (including treatment),
peer education/support, provision of primary health care
and referral to other human services. Of note, age, gen-
der, country of birth, sexual minority, indigenous status
and education were deliberately excluded from factor
analysis as these six variables were considered as less
modifiable demographic characteristics. The factor ana-
lysis used a principle component extraction method,
followed by a Varimax rotation and a Kaiser Normalisa-
tion procedure. To be parsimonious, the threshold of
keeping extracted variables in the final factors was set
where the minimum factor loadings were 0.40 and mini-
mum Eigenvalue was 1.5. Standardised factor scores (i.e.,
mean = 0, sd = 1), produced by the factor analysis, were
used in the next step. For clustering purposes, each fac-
tor score was further dichotomised into >0 and ≤0 (as
weighted sums) to indicate substantial differences be-
tween participants according to each extracted factor. In













1. >2 major life stressors in the past 12 monthsd 96 40.7
2. ‘Some’, ‘most’ or ‘all’ current friends being PWIDd 140 59.3
3. Any current, non-hepatitis C, chronic comorbidity 129 54.7 0.672
4. Ever diagnosed with a mental illness 141 59.7 0.567
5. Social welfare as a main source of current income 171 72.5 0.545
6. >2 injection-caused injuries ever 94 39.8 0.498
7. Current health being only ‘fair’ or ‘poor’ 80 33.9 0.469
8. Perceived current difficulties in managing drug use 130 55.1 0.528
9. Spending ‘some’, ‘most’ or ‘all’ current free time with other PWID 125 53.0 0.493
10. Ever imprisoned 153 64.8 0.485
In the past month
11. Distributive sharing of any other injecting equipmente 66 28.0 0.722
12. Distributive sharing of any needles 47 19.9 0.715
13. Receptive needle or syringe sharing 47 19.9 0.640
14. Receptive injection (i.e., injection by others) 47 19.9 0.585
15. Drug injection at any public spaces (e.g., toilets or parks) 64 27.1 0.525
16. Receptive sharing of any other injecting equipmente 91 38.6 0.499
17. Reuse of any (prior used) needles or syringes 73 30.9 0.475
18. Injection ≥1 per day 101 42.8 0.437
aExplained 20.2 % of total variance; Eigenvalue (rotated solution) = 3.63
bExplained 12.5 % of total variance; Eigenvalue (rotated solution) = 2.26
cExplained 8.3 % of total variance; Eigenvalue (rotated solution) = 1.50
dDropped from factor analysis
eExcluding needles or syringes
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the final step, participants were clustered according to
different combinations of dichotomised factor scores,
reflecting the range of NSP client respondents with vari-
ous degrees of injection and non-injection-related vul-




Of the 236 participants included in the analysis, 47.9 %
(n = 113) was recruited from Primary NSP with co-
located vending machine sites, a further 30.9 % (n = 73)
from stand-alone Primary NSP sites and the rest (n = 50,
21.2 %) from secondary NSP sites.
The overall participant profile has been published else-
where [41]. Briefly, close to two-thirds of the sample
were male (n = 153) aged 39 years (sd = 9.5) and were
predominately Australian-born (n = 212, 89.9 %). A small
proportion self-identified as being other than heterosex-
ual (n = 28, 11.9 %) or being indigenous (n = 52, 22.0 %;
noting that this is an over-representation based on gen-
eral population). This group had other notable sociode-
mographic disadvantage. As a group, the education
attainment level was low where only 55 participants
(23.3 %) had completed high school beyond year 10 (i.e.,
more than 10-year formal schooling), over 70 % of par-
ticipants (n = 171) reported government subsidies as the
main source of their current income and close to two
thirds reported a history of imprisonment (n = 153,
64.8 %) (Table 1).
General health and wellbeing indicators
Apart from varied degrees of sociodemographic disad-
vantage, participants’ health and wellbeing were also
sub-optimal. As shown in Table 1, a third (n = 80,
33.9 %) rated their own health being generally ‘fair’ or
‘poor’, over half of participants reporting ever being diag-
nosed with a mental illness (n = 141, 59.7 %) or having a
current comorbidity (physical or mental) unrelated to
hepatitis C infection (n = 129, 54.7 %). In the previous
12 months, of the 14 listed major life stressors in the
survey, the three most common ones were (in descend-
ing order): any alcohol or drug problems (n = 125,
53.0 %); trouble with the police (n = 76, 32.2 %) and
mental conditions (n = 69, 29.2 %). As the median of
total stressors was 2 (mean = 2.59; sd = 2.09; min = 0;
max = 10), the mental stress indicator used 2 as the
cut-off (i.e., median-split) whereby approximately
40 % (n = 96) reported more than two stressors in the
previous 12 months (Table 1).
Injection- specific indicators
The average age of initiation was 19.9 years (sd = 7.0)
with a majority (n = 218, 92.4 %) having injected in the
previous month. As shown in Table 1, over half of par-
ticipants (n = 130, 55.1 %) perceived difficulties in man-
aging drug use by responding ‘strongly agree’ or ‘agree’
to the statement ‘I find it difficult to manage my drug
use in everyday life’. Second, of the list listed injuries
ever caused by drug injection, the four most commonly
reported ones were (in descending order): collapsed
veins (n = 123, 52.1 %); scarring or bruising (n = 120,
50.8 %); swelling of the hands or feet (n = 90, 38.1 %); and
localised infections (e.g., abscesses or cellulitis, n = 87,
36.9 %). As the median of total injuries was 2 (mean =
2.20; sd = 1.82; min = 0; max = 8), the injection-caused
injury indicator used 2 as the cut-off (i.e., median-split)
whereby approximately 40 % (n = 94) reported more than
two injuries ever (Table 1). Furthermore, this group had
extensive social connections with other PWID, which was
indicated by over half of participants having ‘some’, ‘most’
or ‘all’ friends being PWID (n = 140, 59.3 %) and having
spent ‘some’, ‘most’ or ‘all’ free time with other PWID
(n = 125, 53.0 %) (Table 1).
Eight indicators of risky injection practices were used
in the survey. In the previous month, as shown in
Table 1, the most commonly reported risky practice was
injection at least once per day (n = 101, 42.8 %); followed
by receptive sharing of any injecting equipment other
than needles or syringes (n = 91, 38.6 %) and reuse of
any needles or syringes that had been used by oneself or
others prior (n = 73, 30.9 %). Risky injection practices
that were less common but still reported by a consider-
able proportion of participants included distributive
sharing of any injection equipment other than needles
or syringes (n = 66, 28.0 %) and injection at public spaces
(n = 64, 27.1 %). The three least common risky practices
in the previous month were distributive sharing of nee-
dles, receptive sharing of needles or syringes and recep-
tive injection with each practice being reported by 47
participants (19.9 %).
Extracted cluster factors
The factor analysis produced three factors from 16 vari-
ables, accounting for 41.1 % of total variance (standard
Cronbach alpha = 0.72). The first factor (F1) was labelled
‘recent risky injection’ with an Eigenvalue of 3.63 after ro-
tation and explained 20.2 % of variance. As shown in
Table 1, F1 consisted of all eight risky injection indicators
and were listed in a descending order based on factor
loadings. The second factor (F2) was labelled ‘disadvan-
tage and disability’ with an Eigenvalue of 2.26 after rota-
tion and explained 12.5 % of variance. Also listed in a
descending order based on factor loadings, F2 consisted of
four health indicators (current comorbidity, history of any
mental illness diagnoses, multiple injection-caused injuries
and poor health in general) and one sociodemographic in-
dictor (social welfare dependence). The third factor (F3)
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was labelled ‘drug use milieu’ with an Eigenvalue of 1.50
after rotation and explained 8.4 % of variance. Again,
listed in a descending order based on factor loadings, F3
consisted of two injection-specific indicators (perceived
difficulties in drug management and having spent a con-
siderable proportion of free time with other PWID) and
one sociodemographic indicator (history of any imprison-
ment). Having a considerable proportion of PWID friends
and experiencing multiple life stressors in the previous
12 months failed to load onto any cluster factors.
Client segmentation
The three cluster factors were further dichotomised
on the basis of their standardised factor scores (F1: me-
dian = −0.34; min = −1.25; max = 2.84; F2: median = −0.34;
min = −1.25; max = 2.84; F3: median = 0; min = −2.73;
max = 2.12, respectively). As shown in Fig. 1, for recent
risky injection, 34.7 % (n = 82) of participants were
regarded as having ‘above the average’ vulnerability. For
this particular sub-group with a higher vulnerability in
recent risky injection, 8.4 % (n = 20) had only F1 > 0 (i.e.,
single substantial vulnerability); 17.4 % (n = 41) had F1 > 0
as well as F2 > 0 or F3 > 0 (i.e., double substantial vulner-
ability); and 8.9 % (n = 21) had all three scores above 0
(i.e., triple substantial vulnerability). For social disadvan-
tage and disability, 51.3 % (n = 121) of participants were
regarded as having ‘above the average’ vulnerability,
which could be further divided into 16.1 % (n = 38)
with single substantial vulnerability (i.e., only F2 > 0);
26.3 % (n = 62) with double substantial vulnerability
(i.e., F2 > 0 plus F1 > 0 or F3 > 0) and 8.9 % (n = 21)
triple substantial vulnerability. For drug use milieu,
50.4 % of participants (n = 119) were regarded as hav-
ing ‘above the average’ vulnerability, which can be
further divided into 14.0 % (n = 33) with single sub-
stantial vulnerability (i.e., only F3 > 0); 27.5 % (n = 65)
with double substantial vulnerability (i.e., F3 > 0 plus
F1 > 0 or F2 > 0) and 8.9 % (n = 21) with triple sub-
stantial vulnerability (Fig. 1).
In other words, according to the three cluster factors,
participants could be classified into the following eight,
mutually exclusive groups:
 No substantial vulnerability (n = 40, 16.9 % in total)
 Single substantial vulnerability (n = 91, 38.6 % in
total), which can be further divided into three
groups: recent risky injection only (n = 20, 8.4 %),
social disadvantage and disability only (n = 38,
16.1 %) and drug use milieu only (n = 33, 14.0 %)
 Double substantial vulnerability (n = 84, 35.6 % in
total), which can be further divided into three
groups: both recent risky injection and social
disadvantage and disability (n = 19, 8.1 %); both
recent risk injection and drug use milieu (n = 22,
9.3 %); both social disadvantage and disability and
drug use milieu (n = 43, 18.2 %)
 Triple substantial vulnerability (n = 21, 8.9 %)
Discussion
Using exploratory latent factor analysis, this paper shows
that NSP clients can be essentially differentiated on
three distinctive domains: risky injection, socioeconomic
disadvantage and physical and/or mental comorbidities
and injection-related context/milieu. This key finding
suggests that in countries like Australia where the supply
of sterile injecting equipment supply is already high, there
is an urgent need for NSPs to deliver more client-oriented
services that respond to clients’ real-life priorities and cir-
cumstances, even if some of these fall outside of the cur-
rently defined core business of NSP services.
In the 2014 WHO guidelines on HIV prevention, diag-
nosis, treatment and care for key priority groups, includ-
ing people who inject drugs, attention was paid to the
prevention and management of other co-infections and
comorbidities, including mental health conditions [42].
While this is a welcome advance in understanding, other
life priorities, screening and management of comorbidities
such as mental health were not positioned as associated
Fig. 1 Client segmentation: indices of substantial vulnerability. F1 recent risky injection, F2 disadvantage and disability, F3 drug use milieu
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with risk of HIV transmission (in terms of practice) but as
related to adherence to HIV treatment. This reflects the
nascent literature in relation to understanding broader
factors that can influence risk practice among PWID.
In this paper, just over one third of NSP clients (n = 82,
34.7 %) were classified as having substantial vulnerability
in recent risky injection practices, the smallest proportion
of all three domains. This is consistent with various NSP
surveillance data in Australia where about one quarter to
one-third PWID engage in risky injection practices during
a specified period [5]. We argue that while increased dis-
tribution of sterile injection equipment is necessary, it is
not sufficient to reduce risky injection practice. Indeed,
these data show that measures of vulnerability relating to
drug milieu and social disadvantage were larger than those
relating to injecting risk, when examined individually and
in combination, suggesting that clients’ concerns and
needs are multiple and not necessarily prioritise BBV risk.
In attempting to understand how NSP could be pro-
vided differently and to meet client needs, we demon-
strated that NSP clients could be classified into several
subgroups pertaining to various degrees of vulnerability
in and across each domain. This important finding chal-
lenges the conventional assumption that NSP services
are best oriented towards an ‘average’ client who could
be representative of the entire NSP client population
[36]. Instead, our paper shows that it is important to ad-
dress client heterogeneity based on broader factors that
reflect social determinants of health [43] and indices of
risky injection practices. Our innovative client segmenta-
tion approach based on the exploratory factor analysis
revealed that while over half of NSP clients in this sam-
ple (55.5 %) could be classified as having either no sub-
stantial vulnerability across all three domains or only
one substantial vulnerability in any of the three domains,
the rest (i.e., 44.5 % of the sample) could be considered
as having double or triple substantial vulnerability. For
future NSP service modelling, policy making and re-
source allocation planning, our findings highlight the
importance of taking into account not only clients with
less demanding service needs (that is, 55 % of this sam-
ple) but also those with chronic and more complex
needs, particularly those with substantial vulnerabilities
on aspects of life not related only to injecting drug use.
This paper also sheds new light on the clustered rather
than randomly distributed nature of key indicators. Pre-
vious findings from this project demonstrated a signifi-
cant relationship between recent risky injection practices
and perceived discrimination against PWID by NSP
workers [41]. We argued that this relationship could be
mediated by mental health, that is, the synergistic rela-
tionship between perceived stigma/discrimination and
mental health is important in understanding BBV risk
practice. In the current paper, we demonstrated that of
those classified as having substantial vulnerability in re-
cent risky injection, a majority (62 out of 82 participants)
were also substantially vulnerable in the socioeconomic
and health domain and/or in the drug use milieu domain
(for example, involved in condensed PWID networks).
More importantly, for clients with substantial vulnerability
across all three domains (8.9 %), NSPs could provide or fa-
cilitate better client-oriented services that also support ef-
forts to reduce BBV risk in the long-run.
There are a number of limitations to this study. Our
survey was conducted in one region of Sydney with
about 80 % of participants recruited from Primary NSP
sites. Therefore, the findings from this convenience sam-
ple are not generalisable to other PWID, particularly
those who do not regularly attend NSP services or other
sites with different models of NSP delivery. The sample
size may have limited the statistical power to explore
other measures and detect more nuanced differences.
For future research, a larger sample size and more com-
prehensive measures should be considered to further il-
luminate service needs and broader issues affecting the
lives of PWID. For example, measures of daily life
stressors in the past 12 months could not capture expe-
riences of trauma during early childhood or sustained
through adulthood.
Conclusions
For more than two decades, Australia has maintained a
network of publicly funded and other privately operated
NSP services with a focus on dispensing sterile injecting
equipment, accompanied by BBV-related health promo-
tion. Despite this, sharing of injecting equipment has
persisted at concerning levels [5]. This paper supports
the growing body of literature suggesting that expanding
the volume of equipment distribution alone will not be
sufficient to eradicate risky injection [7, 25, 26]. This
paper extends the literature by pointing out the import-
ant role that more client-tailored NSP service provision
can play to effectively reduce BBV transmission by fur-
ther addressing critical social disadvantage and improv-
ing adverse health and wellbeing status.
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